Follow-up analyses were conducted to examine how inclusion of additional biomarkers related to AD (Aβ40 and Aβ42, total tau), Neurodegeneration (Nf-L) as well as an LBD (α-synuclein) could improve the detection accuracy of the DBT. Here, MAPT is linked to Alzheimer disease.